# JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

> **NCT06944470** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 76 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma
- **PROCEDURE:** surgery
- **RADIATION:** Radiochemotherapy
- **DRUG:** JS207

## Key facts

- **NCT ID:** NCT06944470
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-20
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06944470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06944470, "JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06944470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*